Tag: bioequivalence

Narrow therapeutic index drugs require stricter bioequivalence standards to prevent dangerous side effects or treatment failure. Learn how the FDA, EMA, and Health Canada regulate generics of critical medications like warfarin and levothyroxine.

Replicate study designs are now essential for assessing bioequivalence of highly variable drugs. Learn how full and partial replicate designs work, when to use them, and why they’ve replaced outdated methods in modern BE studies.

Narrow therapeutic index drugs require extreme precision in dosing. Learn why generic versions can be risky, how the FDA regulates them, and what steps you can take to stay safe when switching medications.